Geert Maertens joined Biocartis in 2009 as Chief Scientific Officer (CSO). He is responsible for pipeline development, external collaborations, intellectual property, and Biocartis’ Scientific Advisory Board. Geert started his career at Innogenetics in 1990, where he initiated the hepatitis-C program. He was head of the company’s Infectious Diseases Business Unit, which developed and marketed >20 diagnostic assays for HIV, HBV, HCV, and bacterial typing and resistance during his tenure. With the incorporation of GENimmune as a therapeutic vaccines specialty subsidiary of Innogenetics in September 2007 he became Vice President Corporate Development, a post he held until 2008. Geert obtained his PhD in 1989, frequently lectures at international meetings, and is an inventor with more than 25 viral hepatitis and cancer patent families. He is a reviewer for several scientific journals, evaluates project applications for several European agencies, and has (co-)authored over 90 peer reviewed papers.  

 Cancer, Infectious Diseases, Neurological, Genetic and Metabolic Diseases